A court in New Delhi has given permission for the Drug Controller General of India (DCGI) to process the application by Reliance Life Sciences for a breast cancer drug package.
The so-called package insert had been put on hold by a single judge on the Delhi High Court after Roche ($RHHBY) subsidiary Genentech filed a motion opposing the release of the drug, which is similar to Genentech's Trastuzumab, which is sold under the names of Herclon and Herceptin.
Genentech claimed the Reliance drug had not been "adequately tested," a claim Reliance disputed. Reliance also said other companies like Biocon and Mylan ($MYL) had been allowed by a judge to launch biosimilars of other Genentech drugs, according to a report in the Economic Times.
While Reliance is allowed to move ahead with producing its packaging, the actual launch of its drug is still on hold. The judge set a hearing date for Nov. 30 to consider the case.
- here's the story from the Economic Times